SANDRA GOFINET PASOTO
Projetos de Pesquisa
Unidades Organizacionais
Instituto Central, Hospital das Clínicas, Faculdade de Medicina - Médico
LIM/17 - Laboratório de Investigação em Reumatologia, Hospital das Clínicas, Faculdade de Medicina
LIM/03 - Laboratório de Medicina Laboratorial, Hospital das Clínicas, Faculdade de Medicina
LIM/17 - Laboratório de Investigação em Reumatologia, Hospital das Clínicas, Faculdade de Medicina
LIM/03 - Laboratório de Medicina Laboratorial, Hospital das Clínicas, Faculdade de Medicina
141 resultados
Resultados de Busca
Agora exibindo 1 - 10 de 141
- HOW THE AGE AT DIAGNOSIS MODIFIES THE PHENOTYPE OF PRIMARY SJOGREN SYNDROME: ANALYSIS IN 11,420 PATIENTS (BIG DATA SJOGREN PROJECT)(2019) RETAMOZO, Soledad; ACAR-DENIZLI, Nihan; NG, Wan Fai; HORVATH, Ildiko Fanny; RASMUSSEN, Astrid; SEROR, Raphaele; Li Xiaomei; BALDINI, Chiara; GOTTENBERG, Jacques-Eric; SANDHYA, Pulukool; QUARTUCCIO, Luca; PRIORI, Roberta; HERNANDEZ-MOLINA, Gabriela; ARMAGAN, Berkan; KRUIZE, Aike A.; KWOK, Seung-Ki; KVARNSTROM, Marika; PRAPROTNIK, Sonja; SENE, Damien; BOCCI, Elena Bartoloni; SOLANS-LAQUE, Roser; RISCHMUELLER, Maureen; MANDL, Thomas; SUZUKI, Yasunori; ISENBERG, David; VALIM, Valeria; SEBASTIAN, Agata; NORDMARK, Gunnel; BOOTSMA, Hendrika; NAKAMURA, Hideki; GIACOMELLI, Roberto; DEVAUCHELLE-PENSEC, Valerie; HOFAUER, Benedikt; BOMBARDIERI, Michele; TREVISANI, Virginia Fernandes Moca; HAMMENFORS, Daniel; PASOTO, Sandra; GHEITA, Tamer A.; ATZENI, Fabiola; MOREL, Jacques; VOLLENVEIDER, Cristina; CONSANI-FERNANDEZ, Sandra; MARIETTE, Xavier; RAMOS-CASALS, Manuel; BRITO-ZERON, Pilar
- Neurosarcoidosis during the treatment of primary Sjogren's syndrome: is it a paradoxical effect of rituximab?(2022) CORDEIRO, R. A.; OLIVEIRA, J. L. De; FERRACIOLLI, S. F.; GUEDES, L. K. N.; PASOTO, S. G.
- Influenza A/Singapore (H3N2) component vaccine in systemic lupus erythematosus: A distinct pattern of immunogenicity(2021) FORMIGA, Francisco Fellipe Claudino; SILVA, Clovis Artur; PEDROSA, Tatiana do Nascimento; AIKAWA, Nadia Emi; PASOTO, Sandra Gofinet; GARCIA, Cristiana Couto; CAPAO, Artur Silva Vidal; MARTINS, Victor Adriano de Oliveira; PROENCA, Adriana Coracini Tonacio de; FULLER, Ricardo; YUKI, Emily Figueiredo Neves; VENDRAMINI, Margarete Borges Galhardo; ROSARIO, Debora Cordeiro do; BRANDAO, Leticia Maria Kolachinski Raposo; SARTORI, Ana Marli Christovam; ANTONANGELO, Leila; BONFA, Eloisa; BORBA, Eduardo FerreiraIntroduction Influenza A (H3N2) virus is the most important cause of seasonal influenza morbidity and mortality in the last 50 years, surpassing the impact of H1N1. Data assessing immunogenicity and safety of this virus component are lacking in systemic lupus erythematosus (SLE) and restricted to small reports with other H3N2 strains. Objective This study aims to evaluate short-term immunogenicity and safety of influenza A/Singapore (H3N2) vaccine in SLE. Methods 81 consecutive SLE patients and 81 age- and sex-matched healthy controls (HC) were vaccinated with the influenza A/Singapore/INFIMH-16-0019/2016(H3N2)-like virus. Seroprotection (SP) and seroconversion (SC) rates, geometric mean titers(GMT), and factor increase in GMT(FI-GMT) and adverse events were assessed before and 4 weeks post-vaccination. Disease activity and therapies were also evaluated. Results Before immunization, SLE and HC groups had high SP rates (89% vs 77%, p = 0.061) and elevated GMT titer with higher levels in SLE (129.1(104.1-154.1) vs 54.8(45.0-64.6), p < 0.001). Frequency of two previous years' influenza vaccination was high and comparable in SLE and HC (89% vs 90%, p = 1.000). Four weeks post-vaccination, median GMT increased for both groups and remained higher in SLE compared to HC (239.9(189.5-290.4) vs 94.5(72.6-116.4), p < 0.0001) with a comparable FI-GMT (2.3(1.8-2.9) vs 1.9(1.5-2.3), p = 0.051). SC rates were low and comparable for both groups (16% vs 11%, respectively, p = 0.974). Disease activity scores remained stable throughout the study (p = 1.000) and severe adverse events were not identified. Conclusion Influenza A/Singapore (H3N2) vaccine has an adequate safety profile. The distinct immunogenicity pattern from other influenza A components characterized by a remarkably high pre- and post-vaccination SP rate and high GMT levels may be associated with previous influenza A vaccination. (, NCT03540823).
conferenceObject Immunogenicity and Safety of an Inactivated Virus Vaccine Against SARS-CoV-2 in Patients with Autoimmune Rheumatic Diseases(2021) MEDEIROS-RIBEIRO, Ana; AIKAWA, Nadia; SAAD, Carla Goncalves Schahin; YUKI, Emily Figueiredo Vieira Neves; PEDROSA, Tatiana do Nascimento; FUSCO, Solange; ROJO, Priscila; PEREIRA, Rosa; SHINJO, Samuel; ANDRADE, Danieli; SAMPAIO-BARROS, Percival; RIBEIRO, Carolina; DEVEZA, Giordano; MARTINS, Victor Adriano de Oliveira; SILVA, Clovis Artur; LOPES, Marta; DUARTE, Alberto; ANTONANGELO, Leila; SABINO, Ester; KALLAS, Esper; PASOTO, Sandra Gofinet; BONFA, Eloisa- V Brazilian consensus guidelines for detection of anti-cell autoantibodies on hep-2 cells (vol 59, 28, 2019)(2020) CRUVINEL, Wilson de Melo; ANDRADE, Luis Eduardo Coelho; MUHLEN, Carlos Alberto von; DELLAVANCE, Alessandra; XIMENES, Antonio Carlos; BICHARA, Carlos David; BUENO, Cleonice; MANGUEIRA, Cristovao Luis Pitangueira; BONFA, Eloisa; BRITO, Fabiano de Almeida; FLUMIAN, Fernanda Bull; SILVA, Glaucielen Gomes da; REGO, Jozelia; ANJOS, Lisiane Maria Ericoni dos; SLHESSARENKO, Natasha; PASOTO, Sandra Gofinet; NEVES, Suzane Pretti Figueiredo; VALIM, Valeria; SANTOS, Wilton Silva dos; FRANCESCANTONIO, Paulo Luiz CarvalhoAfter publication of the original article [1], we were notified that there is a mistake in Fig. 2.
- Thalidomide measurement in plasma and dried plasma spot by SPE combined with UHPLC-MS/MS for therapeutic drug monitoring(2022) NOVELLINO, Renata Soares; CHALOM, Marc Yves; ROMANO, Paschoalina; EBNER, Persio de Almeida Rezende; SERAPHIM, Julia Celestino; AMARAL, Ana Carolina Silva do; DUARTE, Nilo Jose Coelho; PEDROSA, Tatiana Do Nascimento; YUKI, Emily Figueiredo Neves; AIKAWA, Nadia Emi; PASOTO, Sandra Gofinet; SILVA, Clovis Artur Almeida da; CARVALHO, Valdemir Melechco; BONFA, Eloisa; KUPA, Leonard de Vinci KandaTweetable abstract Thalidomide measurement in dried plasma spot by ultra-HPLC-MS/MS combined with online SPE was successfully validated and applied in therapeutic drug monitoring. #thalidomide #DPS #chromatography #mass spectrometry Aims: To validate an SPE-ultra-HPLC-MS/MS method for thalidomide (THD) measurement in dried plasma spot (DPS). Methods: Extraction included acetonitrile/water clean-up and online SPE. The LOD, LLOQ, linearity, precision, accuracy, recovery, matrix effect, process efficiency, carryover, stability, drug interference and dilution integrity were assessed. Results: The method was linear from 50 to 2000 ng/ml with a LOD of 20 ng/ml and LLOQ of 50 ng/ml. The coefficient of variation for precision was 0.4-7.9% for intra-assay and 1.3-8.9% for interassay and accuracy was 81.4-97.1%. Adequate matrix effect (100.6-107.0%), recovery (88.7-105.0%) and process efficiency (91.3-109.3%) were registered. DPS was stable for 14 days at room temperature and 45 degrees C and for 4 months at -80 degrees C. The method was applied to quantify THD in both wet plasma and DPS from patients with cutaneous lupus receiving THD treatment. The difference between THD wet plasma and DPS concentration was Conclusion: The method is suitable to quantify THD in DPS.
- Recommendations for evaluation and diagnosis of extra-glandular manifestations of primary sjogren syndrome: results of an epidemiologic systematic review/meta-analysis and a consensus guideline from the Brazilian Society of Rheumatology (articular, pulmonary and renal)(2022) TREVISANI, Virginia Fernandes Moca; PUGLIESI, Alisson; PASOTO, Sandra Gofinet; LOPES, Maria Lucia Lemos; GUEDES, Lissiane Karine Noronha; MIYAMOTO, Samira Tatiyama; FERNANDES, Marilena Leal Mesquita Silvestre; FIALHO, Sonia Cristina de Magalhaes Souza; PINHEIRO, Aysa Cesar; SANTOS, Laura Caldas dos; APPENZELLER, Simone; FIDELIX, Tania; RIBEIRO, Sandra Lucia Euzebio; BRITO, Danielle Christinne Soares Egypto de; LIBORIO-KIMURA, Tatiana Nayara; SANTOS, Maria Carmen Lopes Ferreira Silva; CANTALI, Diego Ustarroz; GENNARI, Juliana D'Agostino; CIVILE, Vinicius Tassoni; PINTO, Ana Carolina Pereira Nunes; ROCHA-FILHO, Cesar Ramos; OLIVEIRA, Fabiola Reis; ROCHA, Aline Pereira da; VALIM, ValeriaSjogren's Syndrome (SS) is an autoimmune disease characterized by lymphocytic infiltration of the exocrine glands and other organs, associated with sicca syndrome but also with systemic involvement with varying degrees of severity. Despite their importance, these systemic manifestations are not routinely evaluated and there is no homogenous approach to their diagnosis or evaluation. To close this gap, a panel of experts from the Brazilian Society of Rheumatology conducted a systematic review and meta-analysis on the identification of epidemiologic and clinical features of these manifestations and made recommendations based on the findings. Agreement between the experts was achieved using the Delphi method. The first part of this guideline summarizes the most important topics, and 11 recommendations are provided for the articular, pulmonary, and renal care of SS patients.
- Anti-DNase I Antibody A New Serological Reactivity in Primary Sjogren Syndrome(2020) GRIFFO, Priscilla; VIANA, Vilma V. S. T.; PASOTO, Sandra G.; LEON, Elaine P.; BONFA, EloisaBackground and Objective: Primary Sjogren syndrome (pSS) is a systemic autoimmune rheumatic disease that particularly affects exocrine glands. Dry eye is one of the most important features of this syndrome, and a recent study reported reduced deoxyribonuclease I (DNase I) activity in the tear of patients with dry eye. We therefore postulated that patients with pSS might have antibodies targeting DNAse I. Methods: We have evaluated in a cross-sectional study 85 patients with pSS (2002 American-European Consensus Group Criteria), 50 rheumatoid arthritis (RA) patients (1987 American College of Rheumatology Criteria) without sicca symptoms, and 88 healthy volunteers. IgG anti-DNase I was detected by enzyme-linked immunosorbent assay using as antigen bovine pancreas enzyme and confirmed by immunoblotting. Results: Age and sex were alike in the 3 groups (p > 0.05). Anti-DNase I was detected in 43.5% of the pSS patients. In contrast, this reactivity was absent in all RA patients (p = 0.0001). Additional comparison of pSS patients with (n = 37) or without (n = 48) anti-DNase I showed that the former group had higher IgG serum levels (2293.2 +/- 666.2 vs 1483.9 +/- 384.6 mg/dL, p = 0.0001) and greater rate of non-drug-induced leukopenia (43% vs 19%, p = 0.02). A multivariate logistic regression analysis identified that only IgG levels were independently associated with anti-DNase I. Conclusions: We describe a high frequency of anti-DNase I antibodies in pSS patients associated with higher serum IgG levels. The lack of this reactivity in RA patients without sicca symptoms suggests that this antibody may be helpful in the differential diagnosis of these diseases.
- Immunogenicity and safety of primary fractional-dose yellow fever vaccine in autoimmune rheumatic diseases(2021) TONACIO, Adriana Coracini; PEDROSA, Tatiana do Nascimento; BORBA, Eduardo Ferreira; AIKAWA, Nadia Emi; PASOTO, Sandra Gofinet; FERREIRA FILHO, Julio Cesar Rente; BARROS, Marilia Mantovani Sampaio; LEON, Elaine Pires; LOMBARDI, Suzete Cleusa Ferreira Spina; MENDRONE JUNIOR, Alfredo; AZEVEDO, Adriana de Souza; SCHWARCZ, Waleska Dias; FULLER, Ricardo; YUKI, Emily Figueiredo Neves; LOPES, Michelle Remiao Ugolini; PEREIRA, Rosa Maria Rodrigues; BARROS, Percival Degrava Sampaio; ANDRADE, Danieli Castro Oliveira de; MEDEIROS-RIBEIRO, Ana Cristina de; MORAES, Julio Cesar Bertacini de; SHINJO, Samuel Katsuyuki; MIOSSI, Renata; DUARTE, Alberto Jose da Silva; LOPES, Marta Heloisa; KALLAS, Esper Georges; SILVA, Clovis Artur Almeida da; BONFA, EloisaBackground Brazil faced a yellow fever(YF) outbreak in 2016-2018 and vaccination was considered for autoimmune rheumatic disease patients(ARD) with low immunosuppression due to YF high mortality. Objective This study aimed to evaluate, prospectively for the first time, the short-term immunogenicity of the fractional YF vaccine(YFV) immunization in ARD patients with low immunossupression. Methods and Results A total of 318 participants(159 ARD and 159 age- and sex-matched healthy controls) were vaccinated with the fractional-dose(one fifth) of 17DD-YFV. All subjects were evaluated at entry(D0), D5, D10, and D30 post-vaccination for clinical/laboratory and disease activity parameters for ARD patients. Post-vaccination seroconversion rate(83.7%vs.96.6%, p = 0.0006) and geometric mean titers(GMT) of neutralizing antibodies[1143.7 (95%CI 1012.3-1292.2) vs.731 (95%CI 593.6-900.2), p< 0.001] were significantly lower in ARD compared to controls. A lower positivity rate of viremia was also identified for ARD patients compared to controls at D5 (53%vs.70%, p = 0.005) and the levels persisted in D10 for patients and reduced for controls(51%vs.19%, p = 0.0001). The viremia was the only variable associated with seroconvertion. No serious adverse events were reported. ARD disease activity parameters remained stable at D30(p>0.05). Conclusion Fractional-dose 17DD-YF vaccine in ARD patients resulted in a high rate of seroconversion rate(> 80%) but lower than controls, with a longer but less intense viremia. This vaccine was immunogenic, safe and did not induce flares in ARD under low immunosuppression and may be indicated in YF outbreak situations and for patients who live or travel to endemic areas.
conferenceObject Preliminary Proteomic Analysis of Saliva from Patients with Sjogren's Syndrome(2015) BOLOGNA, S. B.; SOUZA, M. M.; NUNES, T. B.; NICO, M. M. S.; PASOTO, S. G.; LOURENCO, S. V.